214 related articles for article (PubMed ID: 25512257)
1. SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population.
Yeh YW; Chen CJ; Jang FL; Kuo SC; Chen CY; Liang CS; Ho PS; Yen CH; Shyu JF; Wan FJ; Lu RB; Huang SY
J Psychiatr Res; 2015 Feb; 61():33-9. PubMed ID: 25512257
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure.
Ahmed AT; Biernacka JM; Jenkins G; Rush AJ; Shinozaki G; Veldic M; Kung S; Bobo WV; Hall-Flavin DK; Weinshilboum RM; Wang L; Frye MA
J Affect Disord; 2019 Mar; 246():62-68. PubMed ID: 30578947
[TBL] [Abstract][Full Text] [Related]
3. CYP1A2 Genetic Polymorphism Is Associated With Treatment Remission to Antidepressant Venlafaxine in Han Chinese Population.
Zhu Y; Zhang N; Ren D; Bi Y; Xu F; Niu W; Sun Q; Guo Z; Yuan R; Yuan F; Wu X; Cao Y; Yang F; Wang L; Du L; Li W; Xu Y; Li X; Zhu L; He L; Shi L; He G; Yu T
Clin Neuropharmacol; 2019; 42(2):32-36. PubMed ID: 30875344
[TBL] [Abstract][Full Text] [Related]
4. No association between CYP2C19 genetic polymorphism with treatment remission to antidepressant venlafaxine in Han Chinese population.
Zhang N; Ji L; Chen Z; An L; Ren D; Bi Y; Guo Z; Yuan R; Yuan F; Dong Z; Yin L; Sun X; Yang F; Li X; Yu T; He L; Shi L; He G
Psychiatr Genet; 2020 Feb; 30(1):30-33. PubMed ID: 31842058
[TBL] [Abstract][Full Text] [Related]
5. Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults.
Marshe VS; Maciukiewicz M; Rej S; Tiwari AK; Sibille E; Blumberger DM; Karp JF; Lenze EJ; Reynolds CF; Kennedy JL; Mulsant BH; Müller DJ
Am J Psychiatry; 2017 May; 174(5):468-475. PubMed ID: 28068779
[TBL] [Abstract][Full Text] [Related]
6. SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome.
Proft F; Kopf J; Olmes D; Hempel S; Schmidt B; Riederer P; Deckert J; Pfuhlmann B; Reif A; Unterecker S
Pharmacopsychiatry; 2014 Nov; 47(7):245-50. PubMed ID: 25295552
[TBL] [Abstract][Full Text] [Related]
7. TPH, SLC6A2, SLC6A3, DRD2 and DRD4 Polymorphisms and Neuroendocrine Factors Predict SSRIs Treatment Outcome in the Chinese Population with Major Depression.
Yin L; Zhang YY; Zhang X; Yu T; He G; Sun XL
Pharmacopsychiatry; 2015 May; 48(3):95-103. PubMed ID: 25642918
[TBL] [Abstract][Full Text] [Related]
8. Association between norepinephrine transporter gene (SLC6A2) polymorphisms and suicide in patients with major depressive disorder.
Kim YK; Hwang JA; Lee HJ; Yoon HK; Ko YH; Lee BH; Jung HY; Hahn SW; Na KS
J Affect Disord; 2014 Apr; 158():127-32. PubMed ID: 24655776
[TBL] [Abstract][Full Text] [Related]
9. No Association Between SLC6A4 Gene Polymorphisms With Treatment Remission to Venlafaxine in Han Chinese Depressive Patients.
Wu N; Liu L; Ren D; Yuan F; Bi Y; Guo Z; Hou B; Ji L; Han K; Feng M; Su K; Yu T; Li X; Yang F; Sun X; Dong Z; Yu S; Yi Z; Xu Y; He L; Wu S; Zhao L; Changqun C; Shi Y; He G
Clin Neuropharmacol; 2021 Mar-Apr 01; 44(2):53-56. PubMed ID: 33480616
[TBL] [Abstract][Full Text] [Related]
10. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
11. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
Entsuah AR; Huang H; Thase ME
J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
[TBL] [Abstract][Full Text] [Related]
12. A possible association of the norepinephrine transporter gene in the development of heroin dependence in Han Chinese.
Yeh YW; Lu RB; Tao PL; Shih MC; Huang SY
Pharmacogenet Genomics; 2011 Apr; 21(4):197-205. PubMed ID: 20818294
[TBL] [Abstract][Full Text] [Related]
13. TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients.
Wang HC; Yeh TL; Chang HH; Gean PW; Chi MH; Yang YK; Lu RB; Chen PS
Psychopharmacology (Berl); 2011 Feb; 213(4):773-9. PubMed ID: 20945066
[TBL] [Abstract][Full Text] [Related]
14. Venlafaxine vs. paroxetine in the acute phase of treatment for major depressive disorder among Han Chinese population in Taiwan.
Wu YS; Chen YC; Lu RB
J Clin Pharm Ther; 2007 Aug; 32(4):353-63. PubMed ID: 17635337
[TBL] [Abstract][Full Text] [Related]
15. Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine.
Lee SH; Choi TK; Lee E; Seok JH; Lee SH; Lee HS; Kim SJ
Neuropsychobiology; 2010 Aug; 62(3):198-206. PubMed ID: 20664233
[TBL] [Abstract][Full Text] [Related]
16. Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption.
Shea ML; Garfield LD; Teitelbaum S; Civitelli R; Mulsant BH; Reynolds CF; Dixon D; Doré P; Lenze EJ
Osteoporos Int; 2013 May; 24(5):1741-9. PubMed ID: 23358607
[TBL] [Abstract][Full Text] [Related]
17. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
Wang G; Gislum M; Filippov G; Montgomery S
Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials.
Vis PM; van Baardewijk M; Einarson TR
Ann Pharmacother; 2005 Nov; 39(11):1798-807. PubMed ID: 16189284
[TBL] [Abstract][Full Text] [Related]
19. [Response and remission in depressive patients with anxiety symptoms treated with venlafaxine extended release in primary care].
Roca Benassar M; Baca Baldomero E
Actas Esp Psiquiatr; 2006; 34(3):162-8. PubMed ID: 16736389
[TBL] [Abstract][Full Text] [Related]
20. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
